NO309844B1 - Konserverte, humanproteinholdige legemidler for anvendelse som injeksjons- eller infusjonsoppløsning i form av flerdosepreparater - Google Patents

Konserverte, humanproteinholdige legemidler for anvendelse som injeksjons- eller infusjonsoppløsning i form av flerdosepreparater Download PDF

Info

Publication number: NO309844B1
Authority: NO; Norway
Prior art keywords: preservative; injection; solution; human protein; medicines according
Prior art date: 1991-08-15

Application number

NO940499A

Other languages

English (en)

Norwegian (no)

Other versions

NO940499L (no

NO940499D0 (no

Inventor

Heinrich Woog

Werner Gruber

Hans-Joerg Markl

Gerhard Winter

Fritz Demmer

Original Assignee

Roche Diagnostics Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-15

Filing date

1994-02-14

Publication date

2001-04-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6438353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO309844(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-02-14 Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh

1994-02-14 Publication of NO940499L publication Critical patent/NO940499L/no

1994-02-14 Publication of NO940499D0 publication Critical patent/NO940499D0/no

2001-04-09 Publication of NO309844B1 publication Critical patent/NO309844B1/no

Links

102000003839 Human Proteins Human genes 0.000 title claims abstract description 60
108090000144 Human Proteins Proteins 0.000 title claims abstract description 60
239000007924 injection Substances 0.000 title claims abstract description 50
238000002347 injection Methods 0.000 title claims abstract description 50
239000000243 solution Substances 0.000 title claims description 105
238000002360 preparation method Methods 0.000 title claims description 28
229940126601 medicinal product Drugs 0.000 title claims description 7
238000001802 infusion Methods 0.000 title abstract description 13
239000003755 preservative agent Substances 0.000 claims abstract description 72
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 66
230000002335 preservative effect Effects 0.000 claims abstract description 49
239000000872 buffer Substances 0.000 claims abstract description 34
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims abstract description 27
235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 22
229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 19
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 19
238000004448 titration Methods 0.000 claims abstract description 18
150000001413 amino acids Chemical class 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims abstract description 16
235000001014 amino acid Nutrition 0.000 claims abstract description 15
229960004926 chlorobutanol Drugs 0.000 claims abstract description 14
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims abstract description 4
150000003839 salts Chemical class 0.000 claims abstract description 4
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 3
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 3
239000001630 malic acid Substances 0.000 claims abstract description 3
235000011090 malic acid Nutrition 0.000 claims abstract description 3
239000001509 sodium citrate Substances 0.000 claims abstract description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 3
239000012928 buffer substance Substances 0.000 claims abstract 2
239000003814 drug Substances 0.000 claims description 27
229940079593 drug Drugs 0.000 claims description 22
150000001875 compounds Chemical class 0.000 claims description 15
239000003978 infusion fluid Substances 0.000 claims description 11
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 9
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 9
230000000694 effects Effects 0.000 claims description 7
108090000623 proteins and genes Proteins 0.000 claims description 6
235000018102 proteins Nutrition 0.000 claims description 4
102000004169 proteins and genes Human genes 0.000 claims description 4
239000003513 alkali Substances 0.000 claims description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
102000013566 Plasminogen Human genes 0.000 claims description 2
108010051456 Plasminogen Proteins 0.000 claims description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
235000003704 aspartic acid Nutrition 0.000 claims description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical class OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
239000011976 maleic acid Chemical class 0.000 claims description 2
239000011975 tartaric acid Chemical class 0.000 claims description 2
235000002906 tartaric acid Nutrition 0.000 claims description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
102100028471 Eosinophil peroxidase Human genes 0.000 claims 1
150000001447 alkali salts Chemical class 0.000 claims 1
150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
239000001530 fumaric acid Chemical class 0.000 claims 1
235000011087 fumaric acid Nutrition 0.000 claims 1
235000021317 phosphate Nutrition 0.000 claims 1
150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract description 6
206010020751 Hypersensitivity Diseases 0.000 abstract description 5
230000007815 allergy Effects 0.000 abstract description 5
238000009472 formulation Methods 0.000 abstract description 5
229920001184 polypeptide Polymers 0.000 abstract description 4
102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 3
230000009471 action Effects 0.000 abstract description 3
208000026935 allergic disease Diseases 0.000 abstract description 3
229910000160 potassium phosphate Inorganic materials 0.000 abstract description 3
235000011009 potassium phosphates Nutrition 0.000 abstract description 3
238000003860 storage Methods 0.000 abstract description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract description 2
229960004217 benzyl alcohol Drugs 0.000 abstract description 2
159000000001 potassium salts Chemical class 0.000 abstract description 2
230000009257 reactivity Effects 0.000 abstract description 2
229910052708 sodium Inorganic materials 0.000 abstract description 2
239000011734 sodium Chemical class 0.000 abstract description 2
239000001488 sodium phosphate Substances 0.000 abstract description 2
229910000162 sodium phosphate Inorganic materials 0.000 abstract description 2
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 abstract 1
ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
229940070805 p-chloro-m-cresol Drugs 0.000 abstract 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 67
238000004519 manufacturing process Methods 0.000 description 17
238000007792 addition Methods 0.000 description 15
238000007920 subcutaneous administration Methods 0.000 description 14
229940024606 amino acid Drugs 0.000 description 13
238000001990 intravenous administration Methods 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
102000003951 Erythropoietin Human genes 0.000 description 11
108090000394 Erythropoietin Proteins 0.000 description 11
229940105423 erythropoietin Drugs 0.000 description 11
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 11
239000000546 pharmaceutical excipient Substances 0.000 description 10
239000000126 substance Substances 0.000 description 10
238000000034 method Methods 0.000 description 9
239000008215 water for injection Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
238000004108 freeze drying Methods 0.000 description 6
230000002779 inactivation Effects 0.000 description 6
239000002585 base Substances 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229960002449 glycine Drugs 0.000 description 3
229940124531 pharmaceutical excipient Drugs 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
238000004321 preservation Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
-1 tetralose Chemical compound 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000004471 Glycine Substances 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000009512 pharmaceutical packaging Methods 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
239000007858 starting material Substances 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
KWFAUHHPBGIYQU-UHFFFAOYSA-N 1-chlorobutan-1-ol;1,1,1-trichloro-2-methylpropan-2-ol Chemical compound CCCC(O)Cl.CC(C)(O)C(Cl)(Cl)Cl KWFAUHHPBGIYQU-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229910001508 alkali metal halide Inorganic materials 0.000 description 1
150000008045 alkali metal halides Chemical class 0.000 description 1
229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
229960004074 benzododecinium chloride Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
QDYLMAYUEZBUFO-UHFFFAOYSA-N cetalkonium chloride Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 QDYLMAYUEZBUFO-UHFFFAOYSA-N 0.000 description 1
229960000228 cetalkonium chloride Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
235000013905 glycine and its sodium salt Nutrition 0.000 description 1
102000044890 human EPO Human genes 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000004904 shortening Methods 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

NO940499A 1991-08-15 1994-02-14 Konserverte, humanproteinholdige legemidler for anvendelse som injeksjons- eller infusjonsoppløsning i form av flerdosepreparater NO309844B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4126983A DE4126983A1 (de)	1991-08-15	1991-08-15	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
PCT/EP1992/001822 WO1993003744A1 (de)	1991-08-15	1992-08-10	Verfahren zur herstellung von humanproteinhaltigen, konservierten arzneimitteln für infusions- oder injektionszwecke

Publications (3)

Publication Number	Publication Date
NO940499L NO940499L (no)	1994-02-14
NO940499D0 NO940499D0 (no)	1994-02-14
NO309844B1 true NO309844B1 (no)	2001-04-09

Family

ID=6438353

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO940499A NO309844B1 (no)	1991-08-15	1994-02-14	Konserverte, humanproteinholdige legemidler for anvendelse som injeksjons- eller infusjonsoppløsning i form av flerdosepreparater

Country Status (25)

Country	Link
US (2)	US5503827A (cs)
EP (2)	EP0528313A1 (cs)
JP (1)	JP3670660B2 (cs)
KR (1)	KR100263282B1 (cs)
AT (1)	ATE145138T1 (cs)
AU (2)	AU678756B2 (cs)
CA (1)	CA2115348C (cs)
CZ (1)	CZ284853B6 (cs)
DE (2)	DE4126983A1 (cs)
DK (1)	DK0607156T3 (cs)
ES (1)	ES2094923T3 (cs)
FI (1)	FI112169B (cs)
GE (1)	GEP19981289B (cs)
GR (1)	GR3022037T3 (cs)
HU (1)	HU227421B1 (cs)
IL (1)	IL102775A (cs)
MX (1)	MX9204636A (cs)
NO (1)	NO309844B1 (cs)
RU (1)	RU2091068C1 (cs)
SG (1)	SG66226A1 (cs)
SK (1)	SK281910B6 (cs)
TW (1)	TW351677B (cs)
UA (1)	UA26343C2 (cs)
WO (1)	WO1993003744A1 (cs)
ZA (1)	ZA926122B (cs)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3939346A1 (de) *	1989-11-29	1991-06-06	Behringwerke Ag	Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4126983A1 (de) *	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242863A1 (de) *	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) *	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
SE9300105D0 (sv) *	1993-01-15	1993-01-15	Kabi Pharmacia Ab	Stable protein solution
US5482931A (en) *	1993-06-29	1996-01-09	Ferring Ab	Stabilized pharmaceutical peptide compositions
JP3541054B2 (ja) *	1994-04-21	2004-07-07	ユニ・チャーム株式会社	使い捨ておむつ
US5766582A (en) *	1994-10-11	1998-06-16	Schering Corporation	Stable, aqueous alfa interferon solution formulations
TW426523B (en) *	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
US5888968A (en) *	1995-06-07	1999-03-30	Chiron Corporation	TFPI formulation
EP0837883B1 (en) *	1995-06-07	2005-08-10	Chiron Corporation	Method of solubilizing, purifying, and refolding protein
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
AU1750997A (en) *	1996-01-19	1997-08-11	Eli Lilly And Company	Obesity protein formulations
WO1997026011A1 (en) *	1996-01-19	1997-07-24	Eli Lilly And Company	Obesity protein formulations
TW518219B (en)	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
US20030190307A1 (en) *	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
US7312196B2 (en) *	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6410511B2 (en) *	1997-01-08	2002-06-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
DE19716154A1 (de) *	1997-04-18	1998-10-22	Boehringer Mannheim Gmbh	Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
DK0917879T3 (da) *	1997-11-22	2002-11-04	Roche Diagnostics Gmbh	Forbedret fremgangsmåde til stabilisering af proteiner
JP2001525341A (ja) *	1997-11-28	2001-12-11	ロッシュディアグノスティクスゲゼルシャフトミットベシュレンクテルハフツング	活性ヘッジホッグタンパク質変異体、その調製方法及び医薬への適用
JP3723857B2 (ja) *	1998-02-04	2005-12-07	日本ケミカルリサーチ株式会社	ヒト成長ホルモン含有水性医薬組成物
US6776983B1 (en)	1998-03-06	2004-08-17	Chugai Seiyaku Kabushiki Kaisha	Protein free formulations
US20050203187A1 (en) *	1998-06-01	2005-09-15	Verbiscar Anthony J.	Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
RU2234942C2 (ru) *	1998-07-14	2004-08-27	Корикса Корпорейшн	Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6207718B1 (en)	1998-08-07	2001-03-27	Ontogeny, Inc.	Pharmaceutical compositions containing hedgehog protein
US6979442B1 (en) *	1998-08-17	2005-12-27	Pfizer Inc.	Stabilized protein compositions
ATE401908T1 (de) *	1999-04-09	2008-08-15	Ortho Mcneil Pharm Inc	Pharmazeutische zusammensetzungen von erythropoietin
BR0012674A (pt)	1999-07-22	2002-09-17	Aventis Pharma Inc	Formulações farmacêuticas preservadas
CZ302750B6 (cs) *	1999-07-22	2011-10-19	Aventis Holdings Inc.	Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku
TR200401573T4 (tr)	2000-02-29	2004-08-23	Pfizer Products Inc.	Stabilize edilmiş granülosit koloni uyarıcı faktör
US20020141970A1 (en) *	2001-03-05	2002-10-03	Pettit Dean K.	Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US6818613B2 (en) *	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
RU2218151C2 (ru) *	2001-12-11	2003-12-10	Замаев Ильяс Амсудинович	Способ консервации растворов лекарственных средств
ES2615484T3 (es) *	2002-05-21	2017-06-07	Daiichi Sankyo Company, Limited	Composiciones medicinales que contienen grelina
SI21257A (sl) *	2002-07-17	2004-02-29	LEK farmacevtska dru�ba d.d.	Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
WO2004084859A2 (en) *	2003-03-21	2004-10-07	Nastech Pharmaceutical Company Inc.	Nasal calcitonin formulations containing chlorobutanol
AU2003901515A0 (en) *	2003-04-02	2003-04-17	Norika Holdings	Sterilisation process for pharmaceutical product
ATE553747T1 (de) *	2003-06-10	2012-05-15	Lg Life Sciences Ltd	Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
DE10333317A1 (de) *	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7851433B2 (en) *	2003-08-13	2010-12-14	Novartis Vaccines And Diagnostics, Inc.	Method of purifying TFPI and TFPI analogs
EP1532983A1 (en) *	2003-11-18	2005-05-25	ZLB Bioplasma AG	Immunoglobulin preparations having increased stability
KR101149454B1 (ko) *	2004-08-24	2012-05-25	간가와 겐지	생리활성 펩티드의 액상 제제
DE202005005094U1 (de) *	2005-03-31	2005-07-28	Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh	Ophthalmische Zusammensetzung
AU2006295340B2 (en) *	2005-08-05	2010-11-11	Amgen Inc.	Stable aqueous protein or antibody pharmaceutical formulations and their preparation
DE202006020194U1 (de)	2006-03-01	2007-12-06	Bioceuticals Arzneimittel Ag	G-CSF-Flüssigformulierung
DK2197919T3 (da) *	2007-08-27	2014-07-07	Ratiopharm Gmbh	Flydende formulering af g-csf-konjugat
PT2076243E (pt)	2007-08-27	2014-12-05	Ratiopharm Gmbh	Formulação líquida de g-csf
EP3381445B1 (en)	2007-11-15	2023-10-25	Amgen Inc.	Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP2412385A1 (en) *	2008-02-08	2012-02-01	BioGeneriX AG	Liquid formulation of FSH
US8120369B2 (en)	2009-03-02	2012-02-21	Harris Corporation	Dielectric characterization of bituminous froth
JP6125141B2 (ja)	2009-09-25	2017-05-10	株式会社アールテック・ウエノ	点眼剤
JP6078344B2 (ja)	2010-02-04	2017-02-08	ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト	免疫グロブリン製剤
EP2361636A1 (en)	2010-02-26	2011-08-31	CSL Behring AG	Immunoglobulin preparation and storage system for an immunoglobulin preparation
HUE052280T2 (hu)	2014-12-03	2021-04-28	Csl Behring Ag	Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
WO2018187590A1 (en) *	2017-04-05	2018-10-11	Modernatx, Inc.	Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
AU2019242912B2 (en)	2018-03-28	2025-07-17	Board Of Regents, The University Of Texas System	Identification of epigenetic alterations in DNA isolated from exosomes
US20210024936A1 (en) *	2018-04-09	2021-01-28	Board Of Regents, The University Of Texas System	Therapeutic targeting of oncogenes using exosomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3106073A1 (de) *	1981-02-19	1982-08-19	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen
GB2177914B (en) *	1985-06-04	1989-10-25	Chugai Pharmaceutical Co Ltd	A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
AU648509B2 (en) *	1989-07-14	1994-04-28	Wyeth Holdings Corporation	Stable vaccine compositions containing interleukins
DE4126983A1 (de) *	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en)	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions

1991
- 1991-08-15 DE DE4126983A patent/DE4126983A1/de not_active Withdrawn
1992
- 1992-08-05 TW TW081106209A patent/TW351677B/zh not_active IP Right Cessation
- 1992-08-10 RU RU9294016163A patent/RU2091068C1/ru active
- 1992-08-10 AT AT92916938T patent/ATE145138T1/de active
- 1992-08-10 ES ES92916938T patent/ES2094923T3/es not_active Expired - Lifetime
- 1992-08-10 EP EP92113571A patent/EP0528313A1/de active Pending
- 1992-08-10 AU AU24094/92A patent/AU678756B2/en not_active Expired
- 1992-08-10 US US08/193,002 patent/US5503827A/en not_active Expired - Lifetime
- 1992-08-10 CA CA002115348A patent/CA2115348C/en not_active Expired - Lifetime
- 1992-08-10 SK SK148-94A patent/SK281910B6/sk not_active IP Right Cessation
- 1992-08-10 HU HU9400416A patent/HU227421B1/hu unknown
- 1992-08-10 WO PCT/EP1992/001822 patent/WO1993003744A1/de not_active Ceased
- 1992-08-10 IL IL10277592A patent/IL102775A/en not_active IP Right Cessation
- 1992-08-10 DK DK92916938.1T patent/DK0607156T3/da active
- 1992-08-10 SG SG1996001887A patent/SG66226A1/en unknown
- 1992-08-10 UA UA94005433A patent/UA26343C2/uk unknown
- 1992-08-10 KR KR1019940700453A patent/KR100263282B1/ko not_active Expired - Lifetime
- 1992-08-10 JP JP50407293A patent/JP3670660B2/ja not_active Expired - Lifetime
- 1992-08-10 EP EP92916938A patent/EP0607156B1/de not_active Expired - Lifetime
- 1992-08-10 CZ CZ94287A patent/CZ284853B6/cs not_active IP Right Cessation
- 1992-08-10 DE DE59207523T patent/DE59207523C5/de not_active Expired - Lifetime
- 1992-08-11 MX MX9204636A patent/MX9204636A/es unknown
- 1992-08-14 ZA ZA926122A patent/ZA926122B/xx unknown
- 1992-10-15 GE GEAP19923057A patent/GEP19981289B/en unknown
1994
- 1994-02-14 NO NO940499A patent/NO309844B1/no not_active IP Right Cessation
- 1994-02-14 FI FI940674A patent/FI112169B/fi not_active IP Right Cessation
1996
- 1996-01-30 US US08/593,579 patent/US6303113B1/en not_active Expired - Fee Related
- 1996-12-13 GR GR960403464T patent/GR3022037T3/el unknown
1997
- 1997-03-17 AU AU16339/97A patent/AU710768B2/en not_active Expired

Also Published As

Publication number	Publication date
NO940499L (no)	1994-02-14
AU710768B2 (en)	1999-09-30
CZ284853B6 (cs)	1999-03-17
SK281910B6 (sk)	2001-09-11
KR100263282B1 (ko)	2000-08-01
IL102775A0 (en)	1993-01-31
UA26343C2 (uk)	1999-08-30
AU678756B2 (en)	1997-06-12
HU227421B1 (en)	2011-05-30
EP0607156A1 (de)	1994-07-27
FI940674L (fi)	1994-02-14
CZ28794A3 (en)	1994-08-17
RU94016163A (ru)	1996-08-10
AU1633997A (en)	1997-05-22
JP3670660B2 (ja)	2005-07-13
IL102775A (en)	1999-12-22
CA2115348C (en)	2007-07-17
ZA926122B (en)	1994-02-14
HU9400416D0 (en)	1994-05-30
GR3022037T3 (en)	1997-03-31
TW351677B (en)	1999-02-01
EP0607156B1 (de)	1996-11-13
SG66226A1 (en)	1999-07-20
DK0607156T3 (da)	1997-04-07
SK14894A3 (en)	1994-11-09
FI112169B (fi)	2003-11-14
DE4126983A1 (de)	1993-02-18
HUT67379A (en)	1995-04-28
DE59207523C5 (de)	2006-11-16
DE59207523D1 (de)	1996-12-19
WO1993003744A1 (de)	1993-03-04
ATE145138T1 (de)	1996-11-15
CA2115348A1 (en)	1993-03-04
NO940499D0 (no)	1994-02-14
AU2409492A (en)	1993-03-16
FI940674A0 (fi)	1994-02-14
EP0528313A1 (de)	1993-02-24
JPH06510031A (ja)	1994-11-10
US5503827A (en)	1996-04-02
RU2091068C1 (ru)	1997-09-27
MX9204636A (es)	1993-02-01
US6303113B1 (en)	2001-10-16
ES2094923T3 (es)	1997-02-01
GEP19981289B (en)	1998-05-01

Legal Events

Date	Code	Title	Description
2012-09-10	MK1K	Patent expired

Publication	Publication Date	Title
CA2115348C (en)	2007-07-17	Process for the production of pharmaceutical preparations containing human protein for infusion or injection purposes
EP0904099B1 (en)	2005-11-16	Pharmaceutical formulation containing human growth hormone, histidine and a non-ionic detergent
JP5941496B2 (ja)	2016-06-29	成長ホルモン製剤
RU2191029C2 (ru)	2002-10-20	Композиция стабилизированного гормона роста и способ ее приготовления
EP0910399B1 (en)	2002-09-11	Stable pharmaceutical composition of bdnf
KR20020064141A (ko)	2002-08-07	간실질세포 증식인자 동결건조 제제
PT96016B (pt)	1998-06-30	Processo para a preparacao de uma composicao farmaceutica para a aplicacao subcutanea ou intramuscular contendo polipeptidos
US8841252B2 (en)	2014-09-23	Pharmaceutical formulation
WO1997002832A1 (fr)	1997-01-30	Preparations lyophilisees de hgf
US5552385A (en)	1996-09-03	Pharmaceutical formulation
EP0528314A1 (de)	1993-02-24	Verfahren zur Herstellung von Humanprotein-enthaltenden, gut verträglichen Arzneimitteln für Infusions- oder Injektionszwecke
JPH10265404A (ja)	1998-10-06	ヒト成長ホルモンを含有する医薬製剤
US20030162711A1 (en)	2003-08-28	Pharmaceutical formulation
RU2298415C2 (ru)	2007-05-10	Композиции, включающие гормон роста